The New Yorker article regarding Zohydro is moving the stock today.
This news is reasonable, logical, insightful and informative and is coming from a credible source. The New Yorker, The New York Times, The Wall Street Journal, Barron's, Investor's Business Daily and other news providers that have gained respect over a long period of time are sources of information written 'by adults for adults'.
Speaking of adults, here is an excerpt from the story: " . . . adults with chronic pain deserve to have their suffering mitigated as much as possible."
Articles that are paid infomercials issued by sources such as Motley Fool, Seeking Alpha and The Street with the screaming, antics and showmanship of James Cramer can also move a stock on a daily basis just because what they say is heard or in print. But they pale in comparison and are dangerous to your financial wellbeing, with no guarantees if you follow their advice.
I have a curious price discrepancy at my broker with the stock. The closing price in the quotes area shows $3.23, but the positions balances shows the price as $3.30 on an end of day balance and the value of the stock in my account.
but during the past five years I am very sure that I am in the top 5% of winners in retail investing. No institutional investor can match the gains that I have made, absolutely none and there is absolutely no way, otherwise they would be on the front page of Yahoo Finance. As for other retail investors, I am sure that there are many who have done better than I have. I am in with a big block here with ZGNX at $1.90 on average and if Zogenix stock price goes any lower, as I see some 'playing around' going on, I will load up.
I am not afraid because Zohydro is going to make Zogenix a profit making company and that is only the jumpstart for the company pipeline. I am Long and Strong and have no problem holding for a long term reward and expect to see the stock in double digits depending upon sales of course which I have confidence in.
"Stay thirsty my friends".
7:16AM Aradigm announces appointment of Dr. Juergen Froehlich as Chief Medical Officer (ARDM) 0.17 : Co announced that Juergen Froehlich, MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals (VRTX) where he was Head of Regulatory Affairs, overseeing global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two Breakthrough Designations for the orphan indication of cystic fibrosis.
The person who posted this message is laughable:
And they're coming to take 'takemeserious2004' away ha-ha, they're coming to take him away ho ho he he ha ha, to the funny farm where life is beautiful all the time, and he'll be happy to see those nice young men in their clean white coats and they're coming to take him away ha ha.
This is poor advice.
ZGNX is going up to its price target from here and GALE is a long time gamble with a small 52 Week Low High window and being close to the High and highly volatile bumping up against the ceiling. I suggest that you look at the 'Do the Opposite' Sienfeld episode and do the opposite and sell GALE and buy ZGNX.
Taking your various typographical errors into consideration you are one of the following:
1. Typing too fast
2. An illiterate imposter
Brokerage Oppenheimer & Co upgraded the stock to "outperform" from "perform" after a survey indicated that physicians were likely to prescribe the company's recently approved pain drug, Zohydro.
The drug is an extended release formulation of a common painkiller hydrocodone, which belongs to a widely-used class of pain drugs known as opioids and is approved for use in patients for whom alternate treatment has proved inadequate or ineffective.